Proteases
Proteases, also known as peptidases or proteolytic enzymes, consists of a large number of enzymes catalyzing the hydrolysis of peptide bonds and subsequently resulting in the degradation of protein substrates into amino acids. Proteases are involved in a wide range of human diseases, including cancer, neurodegenerative disorders, inflammatory diseases and cardiovascular diseases. Thus numerous proteases inhibitors (small molecules and proteins) have been identified to block activity of proteases. Proteases inhibitors can be classified into different types based on the class of proteases they inhibit through two general mechanisms, irreversible “trapping” reactions and reversible tight-binding reactions. Proteases inhibitors have been used as diagnostic or therapeutic agents for the treatment of proteases-related diseases.
-
A3461 HIV-1 integrase inhibitorSummary: Uesful for anti-HIV
-
A3653 Nelfinavir MesylateSummary: HIV protease inhibitor,antiretroviral drug for HIV treatment
-
A4069 BMS-707035Target: HIV IntegrasesSummary: HIV-I integrase inhibitor,potent and specific
-
A4070 Elvitegravir (GS-9137)Target: HIV IntegrasesSummary: HIV-1 integrase inhibitor,potent
-
A4071 Fluorouracil (Adrucil)3 CitationTarget: Thymidylate SynthaseSummary: Antitumor agent;inhibitor of thymidylate synthase
-
A4073 Raltegravir (MK-0518)1 CitationTarget: integraseSummary: HIV-1 integrase inhibitor
-
A4074 S/GSK1349572Summary: HIV integrase inhibitor, novel and potent
-
B1122 NelfinavirSummary: HIV-1 protease inhibitor
-
A8566 GSK744 (S/GSK1265744)Summary: HIV integrase inhibitor, oral active and long-acting
-
B5856 GSK1349572 sodiuM saltSummary: Next-generation HIV integrase (IN) inhibitor